TY - JOUR
T1 - Fourth Controlled Human Infection Model (CHIM) meeting – CHIMs in endemic countries, May 22–23, 2023
AU - Kapulu, Melissa
AU - Manda-Taylor, Lucinda
AU - Balasingam, Shobana
AU - Means, Gary
AU - Ayiro Malungu, Mikal
AU - Bejon, Philip
AU - Chi, Primus Che
AU - Chiu, Christopher
AU - Church, E. Chandler
AU - Correa-Oliveira, Rodrigo
AU - Day, Nicholas
AU - Durbin, Anna
AU - Egesa, Moses
AU - Emerson, Claudia
AU - Jambo, Kondwani
AU - Mathur, Roli
AU - Metzger, Wolfram
AU - Mumba, Noni
AU - Nazziwa, Winfred
AU - Olotu, Ally
AU - Rodgers, Jacqueline
AU - Sinyiza, Frank
AU - Talaat, Kawsar
AU - Kamerling, Ingrid
AU - Weller, Charlie
AU - Baay, Marc
AU - Neels, Pieter
PY - 2024/2/1
Y1 - 2024/2/1
N2 - Earlier meetings laid the foundations for Controlled Human Infection Models (CHIMs), also known as human challenge studies and human infection studies, including Good Manufacturing Practice (GMP) production of the challenge agent, CHIM ethics, environmental safety in CHIM, recruitment, community engagement, advertising and incentives, pre-existing immunity, and clinical, immunological, and microbiological endpoints. The fourth CHIM meeting focused on CHIM studies being conducted in endemic countries. Over the last ten years we have seen a vast expansion of the number of countries in Africa performing CHIM studies, as well as a growing number of different challenge organisms being used. Community and public engagement with assiduous ethical and regulatory oversight has been central to successful introductions and should be continued, in more community-led or community-driven models. Valuable initiatives for regulation of CHIMs have been undertaken but further capacity building remains essential.
AB - Earlier meetings laid the foundations for Controlled Human Infection Models (CHIMs), also known as human challenge studies and human infection studies, including Good Manufacturing Practice (GMP) production of the challenge agent, CHIM ethics, environmental safety in CHIM, recruitment, community engagement, advertising and incentives, pre-existing immunity, and clinical, immunological, and microbiological endpoints. The fourth CHIM meeting focused on CHIM studies being conducted in endemic countries. Over the last ten years we have seen a vast expansion of the number of countries in Africa performing CHIM studies, as well as a growing number of different challenge organisms being used. Community and public engagement with assiduous ethical and regulatory oversight has been central to successful introductions and should be continued, in more community-led or community-driven models. Valuable initiatives for regulation of CHIMs have been undertaken but further capacity building remains essential.
KW - Deliberate infection
KW - Endemic diseases
KW - Human challenge
KW - Human infection studies
KW - Infectious diseases
KW - Low- and middle-income countries
KW - Vaccine
U2 - 10.1016/j.biologicals.2024.101747
DO - 10.1016/j.biologicals.2024.101747
M3 - Article
SN - 1045-1056
VL - 85
JO - Biologicals
JF - Biologicals
M1 - 101747
ER -